Amendment No. 3 to the Research Collaboration Agreement, dated April 3, 2024, by and between Nkarta, Inc. and CRISPR Therapeutics AG

Amendment No. 3

to the

RESEARCH Collaboration Agreement

This Amendment No. 3 to the Research Collaboration Agreement (the “Amendment”) is entered into as of April 3, 2024 (“Amendment Effective Date”) by and between Nkarta, Inc. (“Nkarta”) and CRISPR Therapeutics AG (“CRISPR”). Nkarta and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Research Collaboration Agreement, entered into as of May 5, 2021, between Nkarta and CRISPR and as amended by that certain Amendment No. 1 to the Research Collaboration Agreement entered into as of May 4, 2022 and Amendment No. 2 to the Research Collaboration Agreement entered into as of March 8, 2023 (collectively, the “Agreement”). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.

RECITALS

WHEREAS, the Parties desire to amend and restate Section 4.3.1 – Nomination;

NOW, THEREFORE, in consideration of the respective covenants and agreements set forth herein, the Parties hereto agree as follows:

Amendments

“4.3.1 Nomination. Nkarta may provide written notice to CRISPR, nominating a gene editing target to be an Additional Gene-Edited Target (each, a “Nominated Target”), pursuant to the following schedule: [***]. If the Nominated Target is [***], then such Nominated Target shall be designated as an Additional Gene-Editing Target Verified by the Third Party Gatekeeper in accordance with Section 4.3.2.”

MISCELLANEOUS

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their representatives thereunto duly authorized as of the Amendment Effective Date.